UBS Knock-Out AMGN/ DE000UL5SZ53 /
15/11/2024 19:57:41 | Chg.-0.150 | Bid22:00:23 | Demandez à22:00:23 | Sous-jacent | Prix d'exercice | Date d'expiration | Type d'option |
---|---|---|---|---|---|---|---|
0.340EUR | -30.61% | - Bid taille: - |
- Ask la taille: - |
Amgen Inc | 246.6172 USD | 31/12/2078 | Call |
GlobeNewswire
29/08
Great Place To Work Announces the 2024 Best Workplaces in Asia Representing 6.9 Million Employee Exp...
GlobeNewswire
28/08
Prevent Cancer Annual Gala to celebrate three decades of commitment to cancer prevention and early d...
GlobeNewswire
15/08
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of ...
GlobeNewswire
12/08
TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
08/08
CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
08/08
Ardelyx Appoints Experienced Biopharma Executive, Eric Foster, as Chief Commercial Officer
GlobeNewswire
05/08
Avalyn Appoints Erin Lavelle, Seasoned Biopharma Finance Executive, to its Board of Directors
GlobeNewswire
01/08
CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024
GlobeNewswire
22/07
Oxford BioTherapeutics Named Best Tech SME of the Year at Thames Valley Tech & Innovation Awards 202...
GlobeNewswire
02/07
Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Bi...
- La première page
- Retour
- 1
- 2
- 3
- 4
- Suivant
- La dernière page